# A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.

> **NCT05288504** · PHASE2 · COMPLETED · sponsor: **Avalo Therapeutics, Inc.** · enrollment: 91 (actual)

## Conditions studied

- Non-Eosinophilic Asthma

## Interventions

- **DRUG:** AVTX-002
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05288504
- **Lead sponsor:** Avalo Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-24
- **Primary completion:** 2023-05-11
- **Final completion:** 2023-05-11
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2024-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05288504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05288504, "A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05288504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*